---
company: DiaMedica Therapeutics Inc.
ticker: DMAC
form: 8-K
filed: 2026-05-06
accession: 0001437749-26-015218
source: https://www.sec.gov/Archives/edgar/data/1401040/000143774926015218/
---

# DiaMedica Therapeutics (DMAC) earnings release, May 6, 2026

DiaMedica Therapeutics Inc. (DMAC) · Form 8-K, Item 2.02 · Filed 2026-05-06 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1401040/000143774926015218/)

DiaMedica Therapeutics Reports First Quarter 2026

Financial Results and Provides Business Highlights

Minneapolis, Minnesota – May 6, 2026 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today provided a business update and reported financial results for the quarter ended March 31, 2026. Management will host a conference call on Thursday, May 7, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss the Company’s business update and first quarter 2026 financial results.

“We continue to focus on moving our clinical programs forward. Looking ahead, we anticipate four separate preeclampsia data readouts and a readout from our fetal growth restriction trial between now and the end of 2027. Collectively, these datasets are anticipated to inform dose selection for a potential multi-national Phase 3 program in early-onset preeclampsia. We will also weigh the risks and advantages of providing interim updates as clinically meaningful data emerges ahead of formal readouts,” stated Rick Pauls, President and Chief Executive Officer of DiaMedica Therapeutics. "In acute ischemic stroke, ReMEDy2 has surpassed 70% of the required enrollment for, and we are now focused on completing, the interim analysis in the fourth quarter of 2026, which will determine the final number of participants required to complete the study.”

Corporate Highlights

Preeclampsia - Phase 2 IST Clinical Trial:

Fetal Growth Restriction – Phase 2 IST Clinical Trial:

Early-Onset Preeclampsia - Phase 2 Clinical Trial:

Acute Ischemic Stroke ReMEDy2 Phase 2/3 Clinical Developments:

Financial Results Highlights for the First Quarter Ended March 31, 2026

Conference Call and Webcast Information

Management will host a conference call and webcast to discuss its business update and first quarter 2026 financial results on Thursday, May 7, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time:

Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on the Company’s website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until May 14, 2026, by dialing (800) 770-2030 (US Toll Free) and entering the replay passcode: 6195397#.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction, and acute ischemic stroke. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management’s current expectations. When used in this press release, the words “anticipate,” “believe,” “continue,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” or “will,” the negative of these words or such variations thereon or comparable terminology and the use of future dates are intended to identify forward-looking statements and information. The forward-looking statements and information in this press release include statements regarding the timing, nature and requirements for regulatory applications and approvals, including its application for an IND for the study of DM199 as a treatment for preeclampsia and fetal growth restriction and its conducting a Phase 2 trial in these indications; continued ReMEDy2 trial enrollment and timing of the interim analysis; anticipated clinical benefits and success of DM199 for the treatment of preeclampsia, fetal growth restriction and acute ischemic stroke; future R&D and G&A expenses and the Company’s projected cash runway. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Applicable risks and uncertainties include, among others, risks and uncertainties relating to the timing and outcomes of non-clinical studies; risks and uncertainties relating to the timing of studies and trials; risks and uncertainties relating to the clinical expansion into preeclampsia and associated trials; the risk that existing preclinical and clinical data may not be predictive of the results of ongoing or later clinical trials; DiaMedica’s plans to develop, obtain regulatory approval for and commercialize its DM199 product candidate for the treatment of preeclampsia, fetal growth restriction, and acute ischemic stroke and its expectations regarding the benefits of DM199; DiaMedica’s ability to conduct successful clinical testing of DM199 and within its anticipated parameters, site activations, enrollment numbers, costs and timeframes; the perceived benefits of DM199 over existing treatment options; the potential direct or indirect impact of hospital and medical facility staffing shortages, increased tariffs and worldwide global supply chain shortages on DiaMedica’s business and clinical trials, including its ability to meet its site activation and enrollment goals; DiaMedica’s reliance on collaboration with third parties to conduct clinical trials; DiaMedica’s ability to continue to obtain funding for its operations, including funding necessary to complete current and planned clinical trials and obtain regulatory approvals for DM199 for preeclampsia, fetal growth restriction, and acute ischemic stroke; and the risks identified under the heading “Risk Factors” in DiaMedica’s annual report on Form 10-K for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (SEC) and subsequent SEC reports, including our most recent quarterly report on Form 10-Q. The forward-looking information contained in this press release represents the expectations of DiaMedica as of the date of this press release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While DiaMedica may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable laws.

Contact:

Scott Kellen

Chief Financial Officer

Phone: (763) 496-5118 skellen@diamedica.com

For Investor Inquiries:

Mike Moyer

Managing Director, LifeSci Advisors, LLC

Phone: (617) 308-4306 mmoyer@lifesciadvisors.com

Media Contact:

Madelin Hawtin

LifeSci Communications mhawtin@lifescicomms.com

DiaMedica Therapeutics Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

(Unaudited)

DiaMedica Therapeutics Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share amounts)

(Unaudited)

DiaMedica Therapeutics Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

## Financial statements

### Income Statement (Three Months Ended March 31, — (Unaudited) (in thousands))

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 |
|---|---:|---:|
| Operating expenses: | Research and development | 7,987 | 5,656 |
| Operating expenses: | General and administrative | 2,495 | 2,488 |
| Operating expenses: | Operating loss | -10,482 | -8,144 |
| Operating expenses: | Other income, net | 447 | 443 |
| Operating expenses: | Loss before income tax expense | -10,035 | -7,701 |
| Operating expenses: | Income tax expense | -7 | -6 |
| Operating expenses: | Net loss | -10,042 | -7,707 |
| Other comprehensive loss | Unrealized loss on marketable securities | -76 | -18 |
| Other comprehensive loss | Net loss and comprehensive loss | -10,118 | -7,725 |
| Other comprehensive loss | Basic and diluted net loss per share | -0.19 | -0.18 |
| Other comprehensive loss | Weighted average shares outstanding – basic and diluted | 53,793,490 | 42,843,938 |

### Balance Sheet (March 31, 2026 — (Unaudited) (in thousands))

| | March 31, 2026 – (unaudited) | December 31, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 4,868 | 15,647 |
| Current assets: | Marketable securities | 46,463 | 44,243 |
| Current assets: | Prepaid expenses and other assets | 731 | 481 |
| Current assets: | Amounts receivable | 301 | 258 |
| Current assets: | Total current assets | 52,363 | 60,629 |
| Non-current assets: | Deferred offering costs | 400 | 400 |
| Non-current assets: | Operating lease right-of-use asset, net | 175 | 197 |
| Non-current assets: | Property and equipment, net | 142 | 145 |
| Non-current assets: | Total non-current assets | 717 | 742 |
| Non-current assets: | Total assets | 53,080 | 61,371 |
| Current liabilities: | Accounts payable | 3,293 | 1,475 |
| Current liabilities: | Accrued liabilities | 2,340 | 3,545 |
| Current liabilities: | Operating lease obligation | 104 | 101 |
| Current liabilities: | Finance lease obligation | 11 | 11 |
| Current liabilities: | Total current liabilities | 5,748 | 5,132 |
| Non-current liabilities: | Operating lease obligation | 96 | 124 |
| Non-current liabilities: | Finance lease obligation | 1 | 4 |
| Non-current liabilities: | Total non-current liabilities | 97 | 128 |
| Shareholders’ equity: | Paid-in capital | 230,071 | 228,829 |
| Shareholders’ equity: | Accumulated other comprehensive income (loss) | -26 | 50 |
| Shareholders’ equity: | Accumulated deficit | -182,810 | -172,768 |
| Shareholders’ equity: | Total shareholders’ equity | 47,235 | 56,111 |
| Shareholders’ equity: | Total liabilities and shareholders’ equity | 53,080 | 61,371 |

### Cash Flow (Three Months Ended March 31, — (Unaudited) (in thousands))

| | Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 |
|---|---:|---:|
| Cash flows from operating activities: | Net loss | -10,042 | -7,707 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Share-based compensation | 822 | 867 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Amortization of discounts on marketable securities | -190 | -261 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Non-cash lease expense | 22 | 20 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Depreciation | 11 | 11 |
| Changes in operating assets and liabilities: | Amounts receivable | -43 | -17 |
| Changes in operating assets and liabilities: | Prepaid expenses and other assets | -250 | -422 |
| Changes in operating assets and liabilities: | Deposits |  | 1,108 |
| Changes in operating assets and liabilities: | Accounts payable | 1,818 | 567 |
| Changes in operating assets and liabilities: | Accrued liabilities and operating lease liabilities | -1,230 | -1,315 |
| Changes in operating assets and liabilities: | Net cash used in operating activities | -9,082 | -7,149 |
| Cash flows from investing activities: | Purchase of marketable securities | -18,896 | -6,866 |
| Cash flows from investing activities: | Maturities of marketable securities | 16,790 | 13,500 |
| Cash flows from investing activities: | Purchase of property and equipment | -8 | -12 |
| Cash flows from investing activities: | Net cash provided by (used in) investing activities | -2,114 | 6,622 |
| Cash flows from financing activities: | Proceeds from the exercise of stock options | 420 | 94 |
| Cash flows from financing activities: | Principal payments on finance lease obligations | -3 | -3 |
| Cash flows from financing activities: | Net cash provided by financing activities | 417 | 91 |
| Cash flows from financing activities: | Net decrease in cash and cash equivalents | -10,779 | -436 |
| Cash flows from financing activities: | Cash and cash equivalents at beginning of period | 15,647 | 3,025 |
| Cash flows from financing activities: | Cash and cash equivalents at end of period | 4,868 | 2,589 |
| Supplemental disclosure of cash flow information: | Cash paid for income taxes | 6 | 6 |
